Roche's Genentech said it will be shortly submitting a marketing application to the European Medicines Agency for trastuzumab emtansine (T-DM1) and has already applied for a license with the U.S. Food and Drug Administration.
T-DM1 is seen as a successor to Herceptin for Roche, the world's largest maker of cancer drugs.
Copyright 2013 mojeNovosti.com
web developer: BTGcms